Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392)

Market Cap	95.20B
Revenue (ttm)	2.49B
Net Income (ttm)	-294.04M
Shares Out	1.27B
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	158.52
Dividend	0.32 (0.43%)
Ex-Dividend Date	Jun 3, 2024

Volume	6,432,983
Open	74.82
Previous Close	75.00
Day's Range	74.21 - 76.49
52-Week Range	46.30 - 89.89
Beta	2.20
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 18, 2024

About Beijing Wantai Biological Pharmacy Enterprise

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, distributes, and sells infectious disease diagnostic reagents and vaccines in China and internationally. The company provides chemiluminescence series, assembly line series, nucleic acid series, dry type fluorescent immunoassay, and fully automatic blood type analyzer and reagents; ELISA kits; rapid diagnosis; bole series; and supporting reagents. The company was founded in 1991 and is headquartered in Beijing, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1991
• Employees: 3,843
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603392

Financial Performance

In 2023, Beijing Wantai Biological Pharmacy Enterprise's revenue was 5.51 billion, a decrease of -50.73% compared to the previous year's 11.19 billion. Earnings were 1.25 billion, a decrease of -73.65%.